Relapsing Forms of Multiple Sclerosis: Clinical Trials

1 trial for Relapsing Forms of Multiple Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 suspended. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Suspended 1

Follow Relapsing Forms of Multiple Sclerosis: new trials by email Literature Review of Relapsing Forms of Multiple Sclerosis trials Research Report on Relapsing Forms of Multiple Sclerosis

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis
EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD - Relapsing Forms of Multiple Sclerosis
Phase 2SuspendedEmerald Health Pharmaceuticals502021-10-192022-10-21

Narrower conditions

Autoimmune Diseases of the Nervous System (1)  ·  Multiple Sclerosis (1)  ·  Multiple Sclerosis, Relapsing-Remitting (1)  ·  Nervous System Diseases (1)

Broader conditions

Autoimmune Diseases (1)  ·  Demyelinating Autoimmune Diseases, CNS (1)  ·  Demyelinating Diseases (1)  ·  Immune System Diseases (1)

Interventions

BID protein, human (1)

Sponsors

Emerald Health Pharmaceuticals (1)

Countries

Australia (1)  ·  United States (1)